Back to results
US 2017/0246275 A1Published application
Cancer immune-based therapy
AssigneeThe Curators of the University of Missouri
InventorGary Clark
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a novel therapeutic vaccine approach that triggers a therapeutic antitumor response. The inventive approach is to selectively eliminate the carbohydrate sequences from tumor cells without affecting the tumor associated protein epitopes.
Claims21
A composition comprising:
- a cancer cell lysate, wherein the cancer cell lysate comprises modified cancer cells that are characterized by having at least 50% of the carbohydrate functional groups thereon disrupted in comparison to a normal cancer cell from the same type of cancer as the modified cancer cell;
- and
- at least one additional component selected from the group consisting of pharmaceutically-acceptable carriers, adjuvants, diluents, preservatives, antibiotics, and combinations thereof.
The composition of claim 3, wherein said adjuvant is AS04.
A method of treating cancer in a patient comprising the steps of:
- obtaining a sample of cancer cells;
- subjecting said cancer cells to a deglycosylating process wherein the cancer cells have at least 50% of the carbohydrate functional groups thereon disrupted in comparison to a normal cancer cell from the same type of cancer that has not been subjected to a deglycosylating process, thereby resulting in deglycosylated cancer cells;
- lysing said deglycosylated cancer cells;
- producing a cancer cell lysate from said lysed deglycosylated cancer cells;
- and
- administering said cancer cell lysate to the patient.
3 more elements
Dependencies are inferred from the claim text.